Three Companies with UMB Roots Make Progress in Late 2013
Thursday, December 19, 2013
Three health-focused companies with UM Baltimore roots have announced important commercial progress. PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases, announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR), and that it has completed a Series B financing round totaling $22 million. Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer, announced during the quarter that it had completed a $5.3 million registered direct offering. In total, the company raised more than $11 million in 2013. And, Analytical Informatics, a Baltimore-based startup developing state-of-the-art software to help improve quality, performance and efficiency for hospitals and other health delivery organizations, launched a new website and video.
Read more about these news events on the companies' websites at: